Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Jubilant Pharmova Ltd

NSE: JUBLPHARMA · BSE: 530019 · Pharmaceuticals & Biotechnology · 29 announcements

Share price
₹975.00
Market cap
₹15,530 Cr
Revenue (annual)
₹8,280 Cr
Net profit (annual)
₹398.5 Cr
P/E (TTM)
44.1×Sector 47.4×
Promoter holding
47.68%+0.00% QoQ
FII holding
15.87%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

12:42 IST BSE
Legal & Regulatory

Jubilant Pharmova Legal & Regulatory

Jubilant Pharmova Limited received a GST show cause notice proposing a demand of ₹87.31 Crore. The demand includes tax, interest, and penalties for FY 2022-2023.

Value
₹87.31 Cr
10:08 IST BSE
Legal & Regulatory

Jubilant Pharmova Legal & Regulatory

Jubilant Pharmova's subsidiary received a GST show-cause notice for Rs. 105.50 Crore. The company is contesting the demand involving GST and an equal penalty.

Value
₹105.5 Cr
13:47 IST NSE
Legal & Regulatory

Jubilant Pharmova Legal & Regulatory

Jubilant Pharmova received a rectification order deleting a Rs. 22.10 crore tax demand for AY 2020-21. Separate appeals on other grounds remain pending before ITAT.

Value
₹22.10 Cr
18:41 IST NSE
Legal & Regulatory

Jubilant Pharmova Legal & Regulatory

Jubilant Pharmova received a tax rectification order disallowing Rs.53.37 Crore in brought forward losses. The company intends to appeal the decision.

Value
₹53.37 Cr
16:47 IST BSE
Legal & Regulatory

Jubilant Pharmova Legal & Regulatory

Jubilant Pharmova's subsidiary received a tax rectification order reducing adjustments to ₹42.41 Crore. This provides a tax relief of ₹65.48 Crore.

Value
₹65.48 Cr
19:42 IST BSE
Legal & Regulatory

Jubilant Pharmova Legal & Regulatory

Jubilant Pharmova's subsidiary received a Rs. 107.89 Crore income tax demand order. The company intends to appeal, anticipating no material financial impact post-adjudication.

Value
₹107.9 Cr